]>
IRCT20170117032025N9 IRCT 2021-04-07 Hamedan University of Medical Sciences The therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke Study of the therapeutic effect of the combination of altplas and ibtifibatide (integrilin) in comparison with altplas (r-TPA) alone, in the treatment of acute ischemic stroke 2021-04-21 anticipated 50 Complete https://irct.ir/trial/55353 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: For randomization, we use the method of block randomization with blocks with size of 4 and for this purpose, we prepare four sheets of paper. On the two sheets we write the letter I meaning "Intervention" and on the other two sheets we write the letter S meaning "Standard treatment". Mix the sheets together and place them in the desk drawer. Upon referral to any of the eligible patients, one of the sheets will be randomly pulled out and based on this sheet being drawn I or S will be assigned to one of the two intervention or comparison groups. 2 Acute Ischemic Stroke. Intervention 1: Intervention group: In the group receiving the combination drug Altplase and Iftifibatide (Integrilin), Altplase ampoule is used only once and the dose of Altplase is 9 tenths of a milligram per kilogram, of which ten percent is bolus and the rest is injected within one hour. . Optifibatide ampoules are used only once, with a dose of optifibatid (integrilin) ​​of 135 micrograms per kilogram, a bolus dose of 75 percent micrograms per kilogram per minute, and a maintenance dose for two hours. Intervention 2: Control group: In the group receiving Altplase drug, Altplase ampoule is used only once and the dose of Altplase is 9 tenths of a milligram per kilogram, of which ten percent is bolus and the rest is injected within one hour. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is "There is no more information."
public Dr Mahmood Behroozi
Hamadan University of Medical Sciences., Shahid Fahmideh Blvd
Hamadan Iran (Islamic Republic of) 6517838689 +98 81 3838 0535 behrouzi2012@gmail.com Hamedan University of Medical Sciences scientific Dr Mahmood Behroozi
Hamadan University of Medical Sciences., Shahid Fahmideh Blvd
Hamadan Iran (Islamic Republic of) 6517838689 +98 81 3838 0535 behrouzi2012@gmail.com Hamedan University of Medical Sciences Iran (Islamic Republic of) Patients should have a serious measurable neurological defect on the NIHSS stroke scale due to focal ischemia of the brain (NIHSS score> 5). Intravenous therapy should be started within 3 hours of the onset of stroke symptoms. 18 years 80 years Both Suspect subarachnoid hemorrhage, even if the brain CT scan is normal G46.4 Cerebellar stroke syndrome Treatment - Drugs Treatment - Drugs Intervention group: In the group receiving the combination drug Altplase and Iftifibatide (Integrilin), Altplase ampoule is used only once and the dose of Altplase is 9 tenths of a milligram per kilogram, of which ten percent is bolus and the rest is injected within one hour. . Optifibatide ampoules are used only once, with a dose of optifibatid (integrilin) ​​of 135 micrograms per kilogram, a bolus dose of 75 percent micrograms per kilogram per minute, and a maintenance dose for two hours. Control group: In the group receiving Altplase drug, Altplase ampoule is used only once and the dose of Altplase is 9 tenths of a milligram per kilogram, of which ten percent is bolus and the rest is injected within one hour. Cerebral hemorrhage. Timepoint: Admission, discharge and three months later. Method of measurement: By NIHSS(National Institutes of Health Stroke Scale) criteria. Hamedan University of Medical Sciences Approved 2021-03-10 Ethics committee of Hamadan University of Medical Sciences Hamadan University of Medical Sciences., Shahid Fahmideh Blvd Hamadan Hamadan Iran (Islamic Republic of)